Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Year: 2020
Type: article
DOI: 10.1530/ey.17.14.9
Authors: Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE
Institutions: University of Oxford, Pinnacle Clinical Research, Duke University, Duke Medical Center, Medpace (United States), University of California San Diego, The University of Texas at San Antonio Health Science Center, Icahn School of Medicine at Mount Sinai, Florida Atlantic University, Saint Louis University, Madrigal Pharmaceuticals (United States), University of Arizona
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3097209716